Pharmaceutical Executive-11-12-2008

News Analysis
Pharmaceutical Executive

November 12, 2008

AstraZeneca caused a ruckus at the American Heart Association's annual meeting as data was released proving that its statin not only works for its target indication, but also reduced major CV events in patients who don?t have high cholesterol.

News Analysis
Pharmaceutical Executive

November 12, 2008

US heparin manufacturer ordered to turn over contaminated batches of heparin. Just how much of the tainted chemical is on the market?

News Analysis
Pharmaceutical Executive

November 12, 2008

Once considered the future of weight loss drugs, CB-1 antagonists have now been shelved globally. With failures from Pfizer, Merck, and Sanofi-Aventis, analysts say that this is the end of a potential blockbuster therapy.